Related Experiment Video
Updated: Aug 16, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
Effect of encainide and its two major metabolites on cardiac conduction
Abstract:
The effect of encainide and its two major metabolites, O-demethylated encainide (MJ 9444) and 3-O-methoxy encainide (MJ 14030), on cardiac conduction was studied by recording His bundle potentials in isolated perfused rabbit hearts and Purkinje and muscle conduction in vivo in dog hearts after destruction of the atrioventricular node. Both metabolites are 4 to 15 times more potent than encainide in slowing conduction through the atria, the AV-node and the His-Purkinje system of the rabbit heart. They did not differ from each other in potency but MJ 9444 increased the duration and decreased the height of the ventricular potential whereas MJ 14030 had no effect at doses which caused conduction block. In the dog, encainide (0.8-3.2 mg/kg i.v.) slowed conduction of extrasystoles in both Purkinje and muscle at all coupling intervals, increased the effective refractory period and the functional refractory period of the Purkinje pathway. MJ 9444 (0.05-0.4 mg/kg) speeded Purkinje conduction of early (less than 300 msec) without affecting or while slowing conduction of late (greater than 350 msec) extrasystoles. Higher doses (0.4-1.6 mg/kg) slowed conduction at all intervals. The effective refractory period and the functional refractory period were decreased but in some cases returned to control values at the higher doses. Muscle conduction was slowed at doses of 0.4 mg/kg or more. MJ 14030 (0.05-3.2 mg/kg) had variable effects, behaving like MJ 9444 in three experiments but like the parent compound in two others. Only slowing of conduction was seen with the three drugs when heart rate was changed.(ABSTRACT TRUNCATED AT 250 WORDS)
More Related Videos
07:42Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
08:11Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Cardiac Action Potential
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials